<DOC>
	<DOCNO>NCT00050336</DOCNO>
	<brief_summary>The purpose study determine overall survival patient diagnose Stage 3b 4 non-small cell lung cancer ( NSCLC ) treat oral Farnesyl Protein Transferase Inhibitor ( Lonafarnib/SCH 66336 ) combination paclitaxel carboplatin patient treat placebo combination paclitaxel carboplatin .</brief_summary>
	<brief_title>Study Lonafarnib Combination With Paclitaxel Carboplatin Patients With Non-Small Cell Lung Cancer ( Study P01901 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Male female Histologically cytologically 3b 4 ( metastatic ) nonsmall cell lung cancer . Patients must meet subcriteria detail protocol . Age great equal 18 year old ECOG performance status 0 1 Prior diagnosis brain metastasis NSCLC eligible provide brain metastasis adequately treat , patient neurologically stable new progressive brain metastasis identify . Meets protocol requirement specify laboratory value Written inform consent Appropriate use effective contraception childbearing potential Prior basal cell carcinoma carcinoma insitu cervix eligible provide treated evidence disease Prior chemotherapy stage NSCLC Prior surgery radiation therapy within last 2 week incomplete recovery prior procedures therapy Concurrent treatment treatment within last 2 year malignancy Grade 2 great nausea Grade 1 great vomiting ( despite antiemetic medication ) Medical condition would interfere take oral medication Patients bone metastases site disease Pregnant nursing woman Known HIV positivity AIDSrelated illness Patients significant QTc prolongation baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Stage 3b 4 ( metastatic ) non-small cell lung cancer</keyword>
</DOC>